15 January 2024
15 January 2024
Article doesn't exist
Depending on clinical results, the US startup could enter a crowded but fertile thrombectomy market which is predicted to grow to $2.5bn by 2033.
Participants did not experience any serious adverse events or rejection in the Phase Ia trial, which investigated the HIV candidate together with antiretroviral therapy.
The study aims to evaluate the antitumor activity of the vaccine in pancreatic ductal adenocarcinoma (PDAC) patients.
On validating the safety of the cell therapy, the trial will progress to combining IDP-023 with monoclonal antibodies.
The CLIMB study aims to determine the impact of ARINA-1 on exploratory clinical markers in bronchiectasis patients.
The newest acquisition for the company will give access to a web-only platform, which is designed to match sponsors with trial monitors, as PharmAlliance grows its consultation business.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
